Key result
SU-AVR is linked to lower 30-day and one-year mortality versus TAVR.
Its licence doesn't allow us to show a copy here.
Why the study?
The short- and mid-term efficacy and safety of sutureless aortic valve replacement compared with transcatheter aortic valve replacement for aortic stenosis remained unclear due to limited data.
Does sutureless aortic valve replacement improve mortality and valvular leakage compared to transcatheter aortic valve replacement in symptomatic patients with aortic stenosis?
Does sutureless aortic valve replacement improve mortality and valvular leakage compared to transcatheter aortic valve replacement in symptomatic patients with aortic stenosis?
In symptomatic patients with aortic stenosis, SU-AVR offers similar in-hospital and 2-year mortality to TAVR, but may reduce 30-day mortality, 1-year mortality, and valvular leakage.
May support SU-AVR preference for lower 30-day/1-year mortality versus TAVR; reinforces consensus from prior aortic stenosis comparisons.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Obi et al. (2025) studied this question. Sutureless aortic valve replacement was associated with significantly lower 30-day mortality and one-year mortality rates compared to transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: